If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
== Cabinet formation == On March 6 the Cabinet Division issued the de-notification of the caretaker cabinet. The next day PML-N leader Attaullah Tarar said that the federal cabinet would be finalized within the next 48 hours. Adding that HBL President Muhammad Aurangzeb would be considered for the financial portfolio, remarking “The most important portfolio is the finance ministry as the economy has to be revived and the matters with the IMF will have to be taken forward." Shehbaz Sharif would host a dinner together with leaders of the Pakistan Peoples Party (PPP), the Pakistan Muslim League-Quaid (PML-Q), the Istehkam-e-Pakistan Party (IPP) and the Muttahida Qaumi Movement-Pakistan (MQM-P) over Federal Cabinet finalization. PML-N would request for the PPP to join the cabinet, however Bilawal Bhutto would announce that it would support PML-N in government formation without joining cabinet, addressing PPP's CEC meeting “The PPP has decided that while we are not in a position to join the federal government ourselves, nor will we be interested in taking ministries in such a set-up, we also do not want to see political chaos in the country. We do not want to see perpetual crisis in the country,” he said. On March 9 Nawaz Sharif directed Shehbaz Sharif to implement the parties manifesto after the formation of the federal cabinet. Later Nawaz would direct the PM to keep the federal cabinet small in the initial phase. During the meeting, Shehbaz Sharif would table the proposed names of the Federal Cabinet to the PML-N leader.
In this mechanism, the intermediate forms the product by adding another proton to C2. It was expected that solvent protons would contribute to forming the product from the enediol intermediate of the proton-transfer mechanism and when such contributions were not observed in tritiated water, 3H1O, the hydride-transfer mechanism was favored. However, an alternate hypothesis — that the enzyme active site was deeply buried away from water — could not be ruled out and ultimately proved to be correct. The first indications came when ever-increasing temperatures showed ever-increasing incorporation of tritium, which is consistent with proton transfer and unexpected by hydride transfer. The clinching evidence can with studies of the hydrogen-deuterium isotope effect on substrates fluorinated on the methyl group and deuterated on the aldehyde. The fluoride is a good leaving group; the hydride-transfer mechanism predicts less fluoride ion elimination with the deuterated sample, whereas the proton-transfer mechanism predicts more. Experiments on three types of glyoxalase I (yeast, rat and mouse forms) supported the proton-transfer mechanism in every case. This mechanism was finally observed in crystal structures of glyoxalase I.
The result of this pharmacokinetic variability among people is that many people do not receive the right dose to achieve optimal treatment effectiveness with minimized toxic side effects. Some people are overdosed while others are underdosed. For example, in a randomized clinical trial, investigators found 85% of metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) did not receive the optimal therapeutic dose when dosed by the BSA standard—68% were underdosed and 17% were overdosed. There has been controversy over the use of BSA to calculate chemotherapy doses for people who are obese. Because of their higher BSA, clinicians often arbitrarily reduce the dose prescribed by the BSA formula for fear of overdosing. In many cases, this can result in sub-optimal treatment. Several clinical studies have demonstrated that when chemotherapy dosing is individualized to achieve optimal systemic drug exposure, treatment outcomes are improved and toxic side effects are reduced. In the 5-FU clinical study cited above, people whose dose was adjusted to achieve a pre-determined target exposure realized an 84% improvement in treatment response rate and a six-month improvement in overall survival (OS) compared with those dosed by BSA.
Sources: en.wikipedia.org
February 21, 2011 Thailand Thailand's GDP rose 3.8% in the fourth quarter of 2010 after a minor recession caused by GDP contractions of 0.4% in the second quarter and 0.3% in the third quarter of 2010. The growth of the fourth quarter was attributed to a strengthening global economy, along with increasing income levels in the nation and greater liquidity by financial institutions to help the private sector. Full-year growth was recorded at 7.8%.
=== Biosynthetic Spider Silk in E. coli === Ancient Greeks and Romans used spider silk to stop bleeding and aid wound healing and in more modern history, indigenous people in the Solomon Islands as well as Aboriginals created fishing setups from spider silk utilizing it as fishing line. One of the most common methods of producing spider silk biosynthetically utilizes bacteria, such as Escherichia coli (E. coli). The E. coli cell DNA is engineered to express spider silk genes, producing spidroin proteins within the cells. These proteins are then extracted, purified and spun into fibers. While E. coli can produce relatively high yields (e.g., up to 2,700 mg/liter for some MaSp1 variants), process efficiency is very low and many challenges remain in ensuring proper protein folding and solubility for optimal fiber properties, especially for larger spidroin constructs which often cause cell toxicity and death. The table below provides the mechanical properties of the spider silk from a few species to establish a general overview of the mechanical properties. There are then listed a few notable biosynthetic spider silk examples produced in E. coli from recent work.
Twin Peaks is an American chain of sports bars and restaurants based in Lewisville, Texas, which has been described as an "ultimate sports lodge" and breastaurant. The chain is known for having its waitresses, primarily young women and typically referred to as "Twin Peaks Girls", dress in revealing uniforms that consist of cleavage- and midriff-revealing red plaid tops, as well as khaki shorts or denim short shorts. At other times, waitresses wear revealing seasonal or themed outfits. Restaurants are decorated in the theme of a wilderness lodge and serve a mix of American, Southwest and Southern cuisines as well as alcohol. The chain's slogan is "Eats. Drinks. Scenic Views."
=== Eukarya === Xerophilic fungi will usually be found in environments that are sugar rich, and some xerophilic fungi have shown extremely low water activity, as low as .61. Xerophilic fungi include Trichosporonoides nigrescens, Zygosaccharomyces, and Aspergillus penicillioides. Among multi plant life an example of a xerophilic plant group is cacti.
Sources: en.wikipedia.org
==== Physical health ==== Meta-analyses published between 2013 and 2017 show that exercise is associated with reductions in depressive symptoms, fatigue and QoL plus improvements in attention, hyperactivity, impulsivity, social functioning, schizophrenic symptoms, and verbal fluency in various special populations. However, aerobic exercise has no significant effect on anxiety disorders. In 2005 a study conducted by Andrew Steptow and Michael Marmot at University College London, found that happiness is related to biological markers that play an important role in health. The researchers aimed to analyze whether there was any association between well-being and three biological markers: heart rate, cortisol levels, and plasma fibrinogen levels. The participants who rated themselves the least happy had cortisol levels that were 48% higher than those who rated themselves as the most happy. The least happy subjects also had a large plasma fibrinogen response to two stress-inducing tasks: the Stroop test, and tracing a star seen in a mirror image. Repeating their studies three years later Steptow and Marmot found that participants who scored high in positive emotion continued to have lower levels of cortisol and fibrinogen, as well as a lower heart rate. In Happy People Live Longer (2011), Bruno Frey reported that happy people live 14% longer, increasing longevity 7.5 to 10 years and Richard Davidson's bestseller (2012) The Emotional Life of Your Brain argues that positive emotion and happiness benefit long-term health.
Roman A. Zubarev (born 1963) is a Russian-Swedish chemist and professor of medical proteomics in the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, Stockholm, Sweden. His research spans mass spectrometry, proteomics, origin-of-life chemistry, disease biomarker discovery, and related fields.
Late-20th-century DNA sequencing changed lichen systematics, as it did the rest of biology. By the 1990s gene-specific sequencing (e.g., nuclear ribosomal DNA) was accessible, and lichenologists used it to probe deep relationships and test classical schemes. Initial studies centred on nuclear small-subunit rDNA (nuSSU), a slowly evolving gene found in all fungi. Andrea Gargas and co-workers (1995) compared nuSSU sequences from many fungi, including several lichens. Their data supplied the first clear evidence that lichenization arose independently multiple times. Lichen-forming fungi in the sample occupied at least five separate branches of the fungal tree. Three origins lay in the Basidiomycota—for example Omphalina and Multiclavula (mushroom-forming, algal partners) and Dictyonema (cyanobacterial partner). Two further origins occurred in the Ascomycota: one in the large ascolichen clade now placed in Lecanoromycetes, the other in Arthoniomycetes (e.g., some crustose Arthonia species). The pattern contradicted the view that lichens form a single natural group. Instead, 'lichen' is best seen as a functional category—an ecological strategy adopted by disparate fungal lineages. The study suggested that lichen-forming fungi evolved from saprotrophic or parasitic ancestors, not from a single ancestral lichen; some lineages later lost the symbiosis. In other words, the ability to form a lichen could evolve from a non-lichen state multiple times, and perhaps even be lost (as some primarily lichen-forming groups also include non-lichenized fungi).
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.